Search the Community
Showing results for tags 'histologic'.
Found 2 results
J Clin Gastroenterol. 2003 Nov-Dec;37(5):387-91 Tursi A, Brandimarte G, Giorgetti GM. Celiac.com 11/18/2003 - According to the results of an Italian study neither anti-transglutaminase (tTG) nor Anti-endomysium (EMA) antibody levels should be used to determine the state of recovery of gluten-free celiacs. The study looked at 42 consecutively biopsy and blood antibody diagnosed celiac disease patients who went on gluten-free diets, and were then evaluated at 6, 12, and 18 months using anti-transglutaminase (tTG) antibodies and EGDscopy (multiple bioptic samples). For comparison sorbitol H2-breath tests (H2-BT) and anti-endomysium (EMA) antibody tests were also carried out. The results: (A)nti-tTG and EMA were ineffective in assessing the histologic recovery at each follow-up visit (P = NS), while sorbitol H2-BT seems more effective than anti-tTG and EMA in this field (P These results indicate that the biopsy is still the best method to determine recovery from celiac disease, and surprisingly the non-invasive sorbitol H2-breath test was better than both anti-tTG and EMA serology testing in this regard.
Wahab PJ, Meijer JW, Mulder CJ. Department of Gastroenterology and Hepatology, Rijnstate Hospital Arnhem, The Netherlands. Am J Clin Pathol 118(3):459-463, 2002 Celiac.com 10/28/2002 - The following study strongly supports follow-up care and testing for people with celiac disease. As the study found, over 10% of people with diagnosed celiac disease have still not fully recovered even after five years of treatment. To assess histologic recovery in response to gluten withdrawal in celiac disease, 158 patients seen in our hospital during a 15-year period underwent follow-up small intestine biopsies (SIBs) within 2 years after starting a gluten-free diet; further SIBs were done if villous atrophy was present. A modified Marsh classification was used (IIIA, partial villous atrophy; IIIB, subtotal villous atrophy; IIIC, total villous atrophy). Of patients with Marsh IIIA, IIIB, or IIIC lesions, histologic remission was seen in 65.0% within 2 years, 85.3% within 5 years, and 89.9% in long-term follow-up. Eleven patients (7.0%) with persisting (partial) villous atrophy had symptoms and signs of malabsorption and were considered to have refractory celiac disease; 5 of them developed an enteropathy-associated T-cell lymphoma. Children recovered up to 95% within 2 years and 100% in the long-term. Histologic recovery in celiac disease after starting a gluten-free diet takes time and is incomplete or absent in a substantial subgroup of patients (10.1% villous atrophy after 5 years). Systematic follow-up of patients with celiac disease and the malabsorption syndrome and secondary complications is needed.